Clinical trial

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

NCT04081688

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Atezolizumab 1200 MG in 20 ML Injection Normalized identity: 20 ML atezolizumab 60 MG/ML InjectionView linked drug · Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Stereotactic Body Radiation Therapy Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Varlilumab 3 mg/kg Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2019-09-11

PhasePHASE1

Conditions

Refractory Lung Non-Small Cell Carcinomaunresolved

Stage IV Lung Cancer AJCC v8unresolved

Interventions

Atezolizumab 1200 MG in 20 ML InjectionDRUG · verified · RxNorm: 20 ML atezolizumab 60 MG/ML Injection

Stereotactic Body Radiation TherapyRADIATION

Varlilumab 3 mg/kgDRUG

Sponsors & collaborators

Rutgers, The State University of New Jerseylead sponsor

National Cancer Institute (NCI)collaborator

Mapped research locations

New BrunswickNew Jersey, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04081688 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.